AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05151822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training session with the virtual reality mask
Description: Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
Study NCT05151822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring of the device
Description: In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
Study NCT05151822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptability of the device
Description: After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
Study NCT05151822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient state of anxiety
Description: Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
Study NCT04698278 — intervention group
Intervention type: DEVICE
Intervention: PanOptix Trifocal Intraocular Lens
Description: This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
Study NCT05478603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
Study NCT05408533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-Way Foley Urethral Urinary Catheter
Description: Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
Study NCT05408533 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 2-Way Foley Urethral Urinary Catheter
Description: Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
Study NCT04274517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile Water
Description: 1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
Study NCT04274517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3.5% Betadine
Description: 1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
Study NCT05093192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise trial
Description: Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.
Study NCT04274517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.05% Chlorhexidine Gluconate
Description: 1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
Study NCT05761691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Children treated for ECC under general (DGA) and local anesthesia (LA).
Study NCT06300021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG capsule
Description: A dietary supplement product in capsule form containing 300 mg Turmipure Gold®
Study NCT06300021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG ready to drink
Description: Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar
Study NCT06564246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan 20 mg versus Pantoprazole 40 mg
Description: Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
Study NCT04839289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument; Manufacturer A
Description: Commercially available receiver-in-canal hearing instrument from manufacturer A
Study NCT04839289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument; Manufacturer B
Description: Commercially available receiver-in-canal hearing instrument from manufacturer B
Study NCT05561387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Given SC
Study NCT05561387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC
Study NCT06300021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG dairy analog
Description: Ingredient stick containing 300 mg Turmipure Gold® mixed in 240 mL oat milk
Study NCT06300021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG probiotic drink
Description: Ingredient stick containing 300 mg Turmipure Gold® mixed in a 100 mL probiotic yogurt drink base
Study NCT06300021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG gummies
Description: Pectin gummies containing 300 mg Turmipure Gold®
Study NCT06539065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR interactive games
Description: The experimental group received a twelve-week intervention of 36 sessions using VR interactive games in their exercise prescription,
Study NCT06300021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG sport bar
Description: Sport nutrition bar containing 300 mg Turmipure Gold®
Study NCT05013255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15mg
Description: PIO 15mg orally once daily for 2 weeks
Study NCT05013255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: PIO 30mg orally once daily for 2 weeks
Study NCT06480383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 10 mg
Description: ITI-1284 10 mg tablet, taken once daily, sublingual administration.
Study NCT06480383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 20 mg tablet, taken once daily, sublingual administration.
Study NCT06480383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet, taken once daily, sublingual administration
Study NCT06531720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: topical preparation applied on oral mucosa lesion containing 0,2% CHX
Study NCT06531720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Salicylate 8.7 % Oral Gel
Description: topical preparation applied on oral mucosa lesion containing, ethanol-based
Study NCT06531720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: no medication has been prescribed
Study NCT06535529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
Study NCT06535529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
Study NCT04744363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stelara PFS
Description: Pre filled syringes filled with AVT04 and Stelara
Study NCT04744363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara PFS
Description: Pre filled syringes filled with AVT04 and Stelara
Study NCT05526443 — intervention group
Intervention type: DRUG
Intervention: all approved chemotherapeutic agents from second line
Description: all approved chemotherapeutic agents from second line
Study NCT06544473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-beta estradiol
Description: Treatment with orally administered estrogen for 14 days
Study NCT06544473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-beta estradiol
Description: Treatment with transdermally administered estrogen for 14 days
Study NCT06540157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural Beat Music (BBM) Combined with Rhythmic Photic Stimulation (RPS)
Description: Participants rested on a chair for 10 minutes before the intervention. Participants wore over-ear stereo headphones and RPS glasses, receiving 20 minutes of 10Hz BBM (embedded with classic old songs as mask music) and RPS. The BBM and RPS glasses were purchased from George Szeless's mindLightz.
Study NCT06540157 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: Participants rested on a chair for 10 minutes before the intervention. Participants wore the same headphones and RPS glasses as the BBM and RPS group but listened to classic Taiwanese old songs without the 10Hz light stimulation from the RPS glasses.
Study NCT06232538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The level of CNV
Description: The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
Study NCT05164510 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ct-DNA guided therapy
Description: treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
Study NCT04892654 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doravirine
Description: Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
Study NCT04892654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
Study NCT04892654 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir
Description: Antiretroviral, Integrase strand transfer inhibitors
Study NCT04892654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Antiretroviral, Integrase strand transfer inhibitors
Study NCT05430009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Liver SBRT
Description: 24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
Study NCT04892654 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Triple cART regimen
Description: Participant standard triple cART regimen
Study NCT05430009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg every 3 weeks or 400 mg every 6 weeks
Study NCT05763277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Early response evaluation
Description: Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
Study NCT04923386 — intervention group
Intervention type: OTHER
Intervention: None (not interventional)
Description: This is not an intervention
Study NCT04883411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
Description: Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
Study NCT05766761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention condition, the usual prenatal care plus the alcohol intervention
Description: The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
Study NCT05931952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique
Description: Group A: Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for >30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus.
Study NCT05931952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papworth method
Description: Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus.
Study NCT05524207 — intervention group
Intervention type: PROCEDURE
Intervention: carotid artery stenting
Description: Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
Study NCT05066607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
Study NCT05567094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
Study NCT05567094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
Study NCT05561387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT06537908 — intervention group
Intervention type: DRUG
Intervention: Anti-PD-1/PD-L1 antibodies
Description: Anti-PD-1/PD-L1 Intravenous injection for at least 6 months
Study NCT06537908 — intervention group
Intervention type: DRUG
Intervention: Anti-VEGF
Description: Anti-VEGF Intravenous injection for at least 6 months
Study NCT05672173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05672173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection
Study NCT05672173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and/or aspiration
Study NCT05672173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT05672173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05672173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT05672173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT05672173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lisocabtagene Maraleucel
Description: Given IV
Study NCT05672173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05020483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.
Study NCT05020483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
Study NCT05954897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
Description: RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
Study NCT05672173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis
Study NCT05672173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05184413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Description: A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
Study NCT05561387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT05184413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unimodal treatment
Description: An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
Study NCT05190640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: De-Stress Gummies
Description: one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
Study NCT04656782 — intervention group
Intervention type: OTHER
Intervention: Imaging survey
Description: Participation as expert panelist in the imaging survey.
Study NCT04656782 — intervention group
Intervention type: OTHER
Intervention: Facilitation
Description: Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
Study NCT06387563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal activation using pressure biofeedback
Description: PBF assisted abdominal muscle activation training (30 min, 3x /week /4 weeks) Progressive Muscle Relaxation for 5 min Pressure biofeedback assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Progression criteria in training: Maintaining 3 - 5 mmHg pressure on PBF dial while performing abdominal muscle activation.~Exercises for Group For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises
Study NCT06387563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal activation using SEMG biofeedback
Description: SEMG-BF assisted abdominal muscle activation training (30 min, 3x/ week/ 4 weeks) Progressive Muscle Relaxation for 5 min Surface EMG-BF assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Maintaining minimal volumetric contraction of abdominal muscle activation (as per person) on SEMG device with abdominal muscle activation for set frequency~Exercises for Group B For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises